Pamidronat-Dinatrium Hospira (Pamidronate Disodium)

Pamidronate Disodium, the active ingredient in Pamidronat-Dinatrium Hospira, is a bisphosphonate presented as a sterile powder for intravenous infusion use. It is employed in the management of bone resorption disorders, particularly in patients with malignancy‑related hypercalcaemia and those requiring prevention of skeletal complications.

GNH USA supplies Pamidronat-Dinatrium Hospira as a licensed, GDP‑compliant international pharmaceutical supplier serving hospitals, transplant centres and oncology centres worldwide.

Pamidronate Disodium is indicated for conditions that involve excessive bone turnover or calcium dysregulation.

- Malignancy‑related hypercalcaemia: helps lower serum calcium to safer levels. - Osteolytic bone metastases: reduces risk of pathological fractures and bone pain. - Paget’s disease of bone: normalises bone remodeling and alleviates pain. - Prevention of bone loss after stem‑cell transplantation: supports maintenance of skeletal integrity. - Hypercalcaemia of immobilisation: assists in controlling calcium rise during prolonged bed rest.

Adverse reactions to pamidrol ​

Common Side Effects: - Fluor‑like flu‑like symptoms: fever, chills ​ - Musculoskeletal pain ​ - Nausea ​ - Transient elevation ​ -             ... ​ -  ... ​

Serious or Rare ​ -          … ​

Pamidronate should be carefully ​